Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr mice

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Yan, Qingran ^a   Du, Fang ^a   Huang, Xinfang ^a   Fu, Qiong ^a   Chen, Sheng ^a   Dai, Dai ^b   Bao, Chunde ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; B CELL ACTIVATING FACTOR; CD20 ANTIGEN; COMPLEMENT COMPONENT C3; CREATININE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; IGURATIMOD; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 6; BIOLOGICAL MARKER; CHROMONE DERIVATIVE; CYTOKINE; IMMUNOLOGIC FACTOR; SULFONAMIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BLOOD CELL COUNT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; FEMALE; GLOMERULAR DYSFUNCTION; HYPOCOMPLEMENTEMIA; IMMUNE COMPLEX NEPHRITIS; IMMUNOGLOBULIN DEPOSITION; KIDNEY DYSFUNCTION; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NONHUMAN; PLASMA CELL; PROTEINURIA; T LYMPHOCYTE; VASCULITIS; ANIMAL; BIOSYNTHESIS; BLOOD; CHEMISTRY; CYTOTOXICITY; DISEASE MODEL; IMMUNOLOGY; LUPUS NEPHRITIS; LYMPHOCYTE SUBPOPULATION; METABOLISM; MOLECULAR WEIGHT; PATHOLOGY;

MUS;

ANIMALS; BIOLOGICAL MARKERS; CHROMONES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOLOGIC FACTORS; LUPUS NEPHRITIS; LYMPHOCYTE SUBSETS; MICE; MICE, INBRED MRL LPR; MOLECULAR WEIGHT; SULFONAMIDES;

EID: 84907487782     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108273     Document Type: Article

References (37)

1. Du F, Lü L-j, Fu Q, Dai M, Teng J-l, et al. (2008) T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis. Arthritis research & therapy 10.
2. Du F, Lü L-j, Teng J-l, Shen N, Ye P, et al. (2012). T-614 alters the production of matrix metalloproteinases (MMP-1 and MMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro. International Immunopharmacology 13: 54-60.
3. Lü LJTJ, Bao CD, Han XH, Sun LY, Xu JH, et al. (2008). Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial. Chin Med J 121: 615-619.
4. Lu LJ, Bao CD, Dai M, Teng JL, Fan W, et al. (2009). Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Rheum 61: 979-987.
5. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, et al. (2007). Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Modern rheumatology/the Japan Rheumatism Association 17: 1-9.
6. Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, et al. (2001). Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. The Journal of rheumatology 28: 2591-2596.
7. Luo Q, Sun Y, Liu W, Qian C, Jin B, et al. (2013). A Novel Disease-Modifying Antirheumatic Drug, Iguratimod, Ameliorates Murine Arthritis by Blocking IL-17 Signaling, Distinct from Methotrexate and Leflunomide. The Journal of Immunology 191: 4969-4978.
8. Sawada T, Hashimoto S, Tohma S, Nishioka Y, Nagai T, et al. (2000). Inhibition of L-leucine methyl ester mediated killing of THP-1, a human monocytic cell line, by a new anti-inflammatory drug, T614. Immunopharmacology 49: 285-294.
9. Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, et al. (2003). Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology (Oxford, England) 42: 1365-1371.
10. Sanz I, Lee FE-H (2010). B cells as therapeutic targets in SLE. Nat Rev Rheumatol 6: 326-337.
11. Zhou X, Cheng F, Zhang H (2014). Emerging View of Autophagy in Systemic Lupus Erythematosus. International Reviews of Immunology 0: null.
12. Wong HK, Kammer GM, Dennis G, Tsokos GC (1999). Abnormal NF-κB Activity in T Lymphocytes from Patients with Systemic Lupus Erythematosus Is Associated with Decreased p65-RelA Protein Expression. The Journal of Immunology 163: 1682-1689.
13. Martin JC, Baeten DL, Josien R (2014). Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus. Clinical Immunology 154: 1-12.
14. Watson ML, Rao JK, Gilkeson GS, Ruiz P, Eicher EM, et al. (1992). Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. The Journal of Experimental Medicine 176: 1645-1656.
15. Cohen P, Eisenberg R (1991). Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annual review of immunology 9: 243-269.
16. Hunsicker LG, Ruddy S, Carpenter CB, Schur PH, Merrill JP, et al. (1972). Metabolism of Third Complement Component (C3) in Nephritis. New England Journal of Medicine 287: 835-840.
17. Nijnik A, Ferry H, Lewis G, Rapsomaniki E, Leung J, et al. (2006). Spontaneous B cell hyperactivity in autoimmune-prone MRL mice. International immunology 18: 1127-1137.
18. Giese T, Davidson WF (1992). Evidence for early onset, polyclonal activation of T cell subsets in mice homozygous for lpr. The Journal of Immunology 149: 3097-3106.
19. Morse HC, Davidson WF, Yetter RA, Murphy ED, Roths JB, et al. (1982). Abnormalities induced by the mutant gene Ipr: expansion of a unique lymphocyte subset. The Journal of Immunology 129: 2612-2615.
20. Smith HR, Chused TM, Steinberg AD (1984). Cyclophosphamide-induced changes in the MRL-lprlpr mouse: Effects upon cellular composition, immune function, and disease. Clinical immunology and immunopathology 30: 51-61.
21. Ronnblom L, Elkon KB (2010). Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol 6: 339-347.
22. Bossen C, Cachero TG, Tardivel A, Ingold K, Willen L, et al. (2008). TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 111: 1004-1012.
23. Kawano M, Mihara K, Huang N, Tsujimoto T, Kuramoto A (1995). Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 85: 487-494.
24. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, et al. (2007). Long-term safety study of iguratimod in patients with rheumatoid arthritis. Modern rheumatology/the Japan Rheumatism Association 17: 10-16.
25. Reagan-Shaw S, Nihal M, Ahmad N (2008). Dose translation from animal to human studies revisited. The FASEB Journal 22: 659-661.
26. Tsokos G (2011). Systemic lupus erythematosus. The New England journal of medicine 365: 2110-2121.
27. Aikawa Y, Tanuma N, Shin T, Makino S, Tanaka K, et al. (1998). A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis. Journal of neuroimmunology 89: 35-42.
28. Cunnane G, Chan OTM, Cassafer G, Brindis S, Kaufman E, et al. (2004). Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Arthritis & Rheumatism 50: 1539-1548.
29. Lee H-T, Shiao Y-M, Wu T-H, Chen W-S, Hsu Y-H, et al. (2010). Serum BLC/CXCL13 Concentrations and Renal Expression of CXCL13/CXCR5 in Patients with Systemic Lupus Erythematosus and Lupus Nephritis. The Journal of rheumatology 37: 45-52.
30. Sun C-Y, Shen Y, Chen X-W, Yan Y-C, Wu F-X, et al. (2013). The Characteristics and Significance of Locally Infiltrating B Cells in Lupus Nephritis and Their Association with Local BAFF Expression. International Journal of Rheumatology 2013: 9.
31. Schiffer L, Sinha J, Wang X, Huang W, von Gonsdorff G, et al. (2003). Short Term Administration of Costimulatory Blockade and Cyclophosphamide Induces Remission of Systemic Lupus Erythematosus Nephritis in NZB/W F1 Mice by a Mechanism Downstream of Renal Immune Complex Deposition. The Journal of Immunology 171: 489-497.
32. Espeli M, Bökers S, Giannico G, Dickinson HA, Bardsley V, et al. (2011). Local Renal Autoantibody Production in Lupus Nephritis. Journal of the American Society of Nephrology 22: 296-305.
33. Lacotte S, Decossas M, Le Coz C, Brun S, Muller S, et al. (2013). Early differentiated CD138(high) MHCII+ IgG+ plasma cells express CXCR3 and localize into inflamed kidneys of lupus mice. PLoS ONE 8: e58140.
34. Rankin AL, Guay H, Herber D, Bertino SA, Duzanski TA, et al. (2012). IL-21 Receptor Is Required for the Systemic Accumulation of Activated B and T Lymphocytes in MRL/MpJ-Faslpr/lpr/J Mice. The Journal of Immunology 188: 1656-1667.
35. Murray LJ, Lee R, Martens C (1990). In vivo cytokine gene expression in T cell subsets of the autoimmune MRL/Mp-lpr/lpr mouse. European Journal of Immunology 20: 163-170.
36. Jiang C, Loo WM, Greenley EJ, Tung KS, Erickson LD (2011). B Cell Maturation Antigen Deficiency Exacerbates Lymphoproliferation and Autoimmunity in Murine Lupus. The Journal of Immunology 186: 6136-6147.
37. Kyttaris VC, Zhang Z, Kuchroo VK, Oukka M, Tsokos GC (2010). Cutting Edge: IL-23 Receptor Deficiency Prevents the Development of Lupus Nephritis in C57BL/6-lpr/lpr Mice. The Journal of Immunology 184: 4605-4609.